Literature DB >> 26715800

Ciprofloxacin: Spontaneous Bacterial Peritonitis (Prevention).

Joyce A Generali1, Dennis J Cada2.   

Abstract

This Hospital Pharmacy feature is extracted from Off-Label Drug Facts, a publication available from Wolters Kluwer Health. Off-Label Drug Facts is a practitioner-oriented resource for information about specific drug uses that are unapproved by the US Food and Drug Administration. This new guide to the literature enables the health care professional or clinician to quickly identify published studies on off-label uses and determine if a specific use is rational in a patient care scenario. References direct the reader to the full literature for more comprehensive information before patient care decisions are made. Direct questions or comments regarding Off-Label Drug Uses to jgeneral@ku.edu.

Entities:  

Year:  2015        PMID: 26715800      PMCID: PMC4686472          DOI: 10.1310/hpj5008-678

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN: 0018-5787


  8 in total

1.  Management of adult patients with ascites due to cirrhosis.

Authors:  Bruce A Runyon
Journal:  Hepatology       Date:  2004-03       Impact factor: 17.425

Review 2.  Spontaneous bacterial peritonitis: recent guidelines and beyond.

Authors:  R Wiest; A Krag; A Gerbes
Journal:  Gut       Date:  2011-12-06       Impact factor: 23.059

Review 3.  EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis.

Authors: 
Journal:  J Hepatol       Date:  2010-06-01       Impact factor: 25.083

4.  Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study.

Authors:  Javier Fernández; Juan Acevedo; Miriam Castro; Orlando Garcia; Carlos Rodríguez de Lope; Daria Roca; Marco Pavesi; Elsa Sola; Leticia Moreira; Anibal Silva; Tiago Seva-Pereira; Francesco Corradi; Jose Mensa; Pere Ginès; Vicente Arroyo
Journal:  Hepatology       Date:  2012-04-04       Impact factor: 17.425

5.  Ciprofloxacin and long-term prevention of spontaneous bacterial peritonitis: results of a prospective controlled trial.

Authors:  A Rolachon; L Cordier; Y Bacq; J B Nousbaum; A Franza; J C Paris; S Fratte; B Bohn; P Kitmacher; J P Stahl
Journal:  Hepatology       Date:  1995-10       Impact factor: 17.425

6.  Effects of oral ciprofloxacin on aerobic gram-negative fecal flora in patients with cirrhosis: results of short- and long-term administration, with daily and weekly dosages.

Authors:  R Terg; K Llano; S M Cobas; C Brotto; A Barrios; D Levi; W Wasen; M A Bartellini
Journal:  J Hepatol       Date:  1998-09       Impact factor: 25.083

7.  Ciprofloxacin in primary prophylaxis of spontaneous bacterial peritonitis: a randomized, placebo-controlled study.

Authors:  Rubén Terg; Eduardo Fassio; Mónica Guevara; Mariano Cartier; Cristina Longo; Romina Lucero; Cristina Landeira; Gustavo Romero; Nora Dominguez; Alberto Muñoz; Diana Levi; Carlos Miguez; Raquel Abecasis
Journal:  J Hepatol       Date:  2008-02-14       Impact factor: 25.083

8.  Patterns of antimicrobial resistance in the causative organisms of spontaneous bacterial peritonitis: a single centre, six-year experience of 1981 samples.

Authors:  Sara Sheikhbahaei; Alireza Abdollahi; Nima Hafezi-Nejad; Elham Zare
Journal:  Int J Hepatol       Date:  2014-03-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.